share_log

Hims & Hers Falls 11% After FDA Announces Shortage Has Ended for Eli Lilly Drugs

moomooニュース ·  10/03 10:01

$Hims & Hers Health (HIMS.US)$ dropped 11% after the Food and Drug Administration announced  shortages of Eli Lilly's obesity and diabetes drugs Zepbound and Mounjaro have ended.

The company sells direct-to-consumer generic prescription medicines, including weight-loss drugs, and with Lilly's shortages, had taken advantage by creating copycat treatments.

Investors will keep their eyes on the upcoming Hims & Hers Health earnings report. Prior to Thursday's news, shares had increased  33.17% in the last month.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする